Aktuell: Deutsche Ophthalmologische Gesellschaft zeichnet hochkarätige Veröffentlichungen zu neuen Therapieansätzen bei Netzhauterkrankungen aus: Wissenschaftspreis der Stiftung Auge für Dr. Aysegül Tura (Universitäts-Augenklinik Lübeck)
Durchsuchen Sie hier die Seiten zur altersbedingten Makuladegeneration:
Overview Avastin / Lucentis
Published on 07/10/11 at 10:15am
Novartis has been forced to cut the Swiss price of its eye drug Lucentis by 30% after sharp negotiations with the government.
The deal was negotiated by Switzerland's Health Minister Didier Burkhalter and could save the country hundreds of millions of francs over the next five years, according to local newspaper La Matin.
Lucentis (ranibizumab) is licensed in Europe to treat the eye disease wet age-related macular oedema, a leading cause of blindness in the over fifties.
But ophthalmologists have been opting to treat patients with Roche's cancer drug Avastin (bevacizumab), which - though not licensed for wet AMD - is chemically similar to Lucentis and around 20 times cheaper.
Roche co-markets Lucentis with Novartis in the US, and has no plans to seek a new licence for Avastin for the eye disease because it would be undercutting its own drug.
According to La Matin Burkhalter knew this, but still pressured Roche to conduct new trials for Avastin in wet AMD in order to persuade Novartis - whose head office is in Switzerland - to negotiate over the price of Lucentis.
The price cut could go even deeper. A ministry spokesman for the health ministry told La Matin: "We have been successful on this last point with a drop of 30%," but added that if nationwide sales of the drug exceed 108 million francs, then the price will have to drop again.
This could have repercussions across other countries as Switzerland acts as a reference for many other markets, although many countries are already investigating using Avastin off-label without Roche's consent.
This is happening in the US where nationally-funded trials are ongoing to see if Avastin is as safe and effective as Lucentis in treating wet AMD.
The main impetus is cost as analysts are projecting that switching treatments could save the US $1 billion over the next two years.
Both Roche and Novartis have fought against the use of Avastin in wet AMD, saying that patients are at risk of infections and other side effects from using Avastin off-label because it has not been studied for safety in wet AMD patients.
But the Swiss price cut represents a realisation that Lucentis must still compete with Avastin, even if it doesn't want to.
This is especially true now that austerity measures start to take aim at healthcare budgets, with drugs like Lucentis representing an easy target for swift savings.
7 Ferienwohnungen sind in diesem Ferienhof mit Reitbetrieb am Strand Holnis untergebracht. Alle Ferienwohnungen sind mit SAT-TV ausgestattet. Jede Wohnung verfügt über eine gemütliche Eßecke und Sitzgarnitur. Ein Duschbad gehört ebenfalls zu jeder Ferienwohnung. Großer Garten, Grillhütte und Spielplatz sind am Haus!